HCV / Hepatitis

Atea Pharmaceuticals will present the full clinical study at the upcoming EASL Congress in May.

While 254 million affected globally with HBV, the disease remains endemic in Nigeria due to imperfect vaccination efficacy and limited coverage

Universal hepatitis C screening updates have influenced testing numbers, and resulted in a gradual increase for all women with a pronounced increase in pregnant women.

With valid phase 2 results, hydronidone could pave the way for first antifibrotic treatment in chronic liver disease.

Yael David, PhD, discusses how cccDNA nucleosome positioning drives HBV transcription and how CBL137 disrupts this process to block infection.

Precision BioSciences received the designation for its gene editing therapy, PBGENE-HBV, developed to eliminate the root cause of chronic hepatitis B virus (HBV).

The loss of surveillance capabilities complicates efforts to control hepatitis outbreaks, explore new preventive treatments, and support new research trials.

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Although there have been decreases in newly reported chronic hepatitis C cases across many demographics, the need to get people screened and given therapy in the same visit remains vital.

Switching from tenofovir disoproxil fumarate to besifovir dipivoxil maleate improves renal and bone health without compromising antiviral efficacy.

This open-label trial will compare the combination of the company’s therapies, bemnifosbuvir and ruzasvir, with another hepatitis C combination regimen.

Long-term clinical and economic benefits of an inclusive national HCV program targeting mothers and infants, two often overlooked populations.

Development of a monoclonal antibody targeting mucormycosis, WHO’s call for improved fungal diagnostics and therapies, Bayesian dosing to optimize antimicrobial therapy, and more.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment.

Despite a large number of new infections globally, an international survey shows real reservations by people to get screened and limited knowledge about the risks, thus preventing them from seeking needed treatment.

Twenty organizations asked the high court to consider the federal government’s position on pre-exposure prophylaxis (PrEP) and HIV and hepatitis testing.

In a randomized control study, the antiviral demonstrated reduced risk and could potentially influence treatment management for patients with a moderate or high viral load.

In a small trial, the Hecolin hepatitis E vaccine demonstrated further utility outside of previous study parameters.

As 2024 winds down, we're looking back on some of the stories that caught readers' eyes on Contagion related to the variety of hepatitis virus infections.

This week, concerns over mutated avian flu in a Louisiana patient, the potential of ibuzatrelvir for COVID-19 treatment, a comparison of ceftolozane-tazobactam and ceftazidime-avibactam for pneumonia treatment, and more.

Lower CD4+ cell counts, HCV genotype 4, and recent injection drug use were linked to unsuccessful DAA treatment in people with HCV and HIV.

Study shows this could reduce hepatitis C and injection-related infections, with each dollar invested saving $2 in treatment costs.

A study found deploying peers with lived experience in illicit drug use increased the rate of people diagnosed, treated, and cured of the disease.

In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.

The development of CRMA-1001, a potential functional cure for chronic hepatitis B and D, is set to enter clinical trials in 2025.

Focused prevention policies and support systems have shown to reduce HCV prevalence in at-risk groups. Addressing factors like IDU, lack of income, and alcohol misuse through targeted education and interventions is essential to mitigate HCV infection rates locally and globally.

Study explores the receptiveness to long-acting antiviral solutions in low- and middle-income countries.

The combination therapy’s developer, Atea Pharmaceuticals, is looking to initiate a phase 3 study in early 2025.

This study explores HLA-E as a target to activate the immune system in HBV infection, identifying a stable peptide, Env371-379 L6I, that effectively triggers T-cell responses.